Bridging Radiotherapy to Immunotherapy: The IFN–JAK–STAT Axis
The unprecedented successes of immunotherapies (IOs) including immune checkpoint blockers (ICBs) and adoptive T-cell therapy (ACT) in patients with late-stage cancer provide proof-of-principle evidence that harnessing the immune system, in particular T cells, can be an effective approach to eradicat...
Guardado en:
Autores principales: | Lewis Zhichang Shi, James A. Bonner |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
MDPI AG
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/186df8d319744d2c830cfb34d6ea2a78 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
EGCG Inhibits Tumor Growth in Melanoma by Targeting JAK-STAT Signaling and Its Downstream PD-L1/PD-L2-PD1 Axis in Tumors and Enhancing Cytotoxic T-Cell Responses
por: Dinoop Ravindran Menon, et al.
Publicado: (2021) -
Janus Kinase Inhibitors in the Treatment of Vitiligo: A Review
por: Fei Qi, et al.
Publicado: (2021) -
Proteasome inhibitors restore the STAT1 pathway and enhance the expression of MHC class I on human colon cancer cells
por: Yi-Hsin Liang, et al.
Publicado: (2021) -
Edaravone alleviates cell apoptosis and mitochondrial injury in ischemia-reperfusion-induced kidney injury via the JAK/STAT pathway
por: Zhao,Xiaoying, et al.
Publicado: (2020) -
JQ-1 ameliorates schistosomiasis liver fibrosis by suppressing JAK2 and STAT3 activation
por: Han Ding, et al.
Publicado: (2021)